Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | GRK6 | P43250 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648057 | 0.93 | KMT2A (0.40) | C5AR1TLR7HDAC1PPARGPPARA | |
| SCHEMBL1913014 | 0.90 | C5AR1 (0.42) | C5AR1TLR7HDAC1FAAHPPARG | |
| SCHEMBL5135950 | 0.86 | LPAR1 (0.42) | C5AR1TLR7HDAC1PPARGPPARA | |
| SCHEMBL5135893 | 0.86 | TLR7 (0.49) | C5AR1TLR7 | |
| SCHEMBL648900 | 0.85 | C5AR1 (0.42) | C5AR1TLR7HDAC1PPARGPPARA | |
| SCHEMBL648838 | 0.84 | C5AR1 (0.43) | C5AR1HDAC1PPARGPPARAKDM4E | |
| SCHEMBL649303 | 0.84 | C5AR1 (0.45) | C5AR1HDAC1FAAHPPARGPPARA | |
| SCHEMBL650854 | 0.83 | C5AR1 (0.39) | C5AR1TLR7HDAC1FAAH | |
| SCHEMBL5135455 | 0.82 | TLR7 (0.40) | C5AR1TLR7HDAC1KDM4EHPGD | |
| SCHEMBL648586 | 0.82 | C5AR1 (0.39) | C5AR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |